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Background: Herbal remedies are widely used in many malaria endemic countries to treat patients, in particular in the
absence of anti-malarial drugs and in some settings to prevent the disease. Herbal medicines may be specifically designed
for prophylaxis and/or for blocking malaria transmission to benefit both, the individual consumer and the community at
large. Neem represents a good candidate for this purpose due to its inhibitory effects on the parasite stages that cause
the clinical manifestations of malaria and on those responsible for infection in the vector. Furthermore, neem secondary
metabolites have been shown to interfere with various physiological processes in insect vectors. This study
was undertaken to assess the impact of the standardised neem extract NeemAzal® on the fitness of the malaria
vector Anopheles stephensi following repeated exposure to the product through consecutive blood meals on
treated mice.
Methods: Batches of An. stephensi mosquitoes were offered 5 consecutive blood meals on female BALB/c
mice treated with NeemAzal® at an azadirachtin A concentration of 60, 105 or 150 mg/kg. The blood feeding
capacity was estimated by measuring the haematin content of the rectal fluid excreted by the mosquitoes
during feeding. The number of eggs laid was estimated by image analysis and their hatchability assessed by
direct observations.
Results: A dose and frequency dependent impact of NeemAzal® treatment on the mosquito feeding capacity,
oviposition and egg hatchability was demonstrated. In the 150 mg/kg treatment group, the mosquito feeding
capacity was reduced by 50% already at the second blood meal and by 50 to 80% in all treatment groups at
the fifth blood meal. Consequently, a 50 – 65% reduction in the number of eggs laid per female mosquito
was observed after the fifth blood meal in all treatment groups. Similarly, after the fifth treated blood meal
exposure, hatchability was found to be reduced by 62% and 70% in the 105 and 150 mg/kg group respectively.
Conclusions: The findings of this study, taken together with the accumulated knowledge on neem open
the challenging prospects of designing neem-based formulations as multi-target phytomedicines exhibiting
preventive, parasite transmission-blocking as well as anti-vectorial properties.
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Recent global estimates suggest that over the last decade
malaria-related mortality has been reduced by about
49% in the WHO African region [1]. The successful re-
duction of malaria-related mortality is partly due to the
deployment of free or subsidised insecticide-treated bed
nets (ITNs) and artemisinin-based combination therapy
(ACT), as well as indoor residual spray (IRS) implemen-
tation at a large scale. These malaria control strategies
benefit the individual users and confer significant bene-
fits to the local communities by reducing parasite trans-
mission [2,3] (reviewed in [4]).
However, the currently used control tools may become
redundant due to the evolution of resistance, by parasite
and vector populations to the few available effective
drugs and insecticides. For example, the emerging evi-
dence of mosquito resistance to pyrethroid chemicals
used for ITNs impregnation [5-10] and resistance to
dichlorodiphenyltrichloroethane (DDT) and other che-
micals used in IRS [11] threatens the sustainability of
current malaria control interventions. In addition, Plas-
modium falciparum resistance to artemisinin derivatives
[1,12-14], a few years after most governments of en-
demic regions changed to ACTs as first line treatment
for malaria, represents yet another major threat to mal-
aria case management. While other drug combinations
with chloroquine, quinine and sulphadoxine pyrimeth-
amine are known to decrease gametocytaemia preva-
lence and mosquito infectiveness [15-17], recent studies
have shown that children treated with ACT combina-
tions remain infective to mosquitoes after day 14 of
treatment initiation [18] suggesting a rebound effect of
gametocytaemia [19].
These challenges highlight a need for additional tools
and new strategies for malaria control and elimination.
Scientifically validated herbal remedies, for instance,
may offer such a tool and constitute a source for the de-
velopment of new drugs and/or improved phytomedi-
cines. As shown by the history of anti-malarial drugs,
traditional medicinal knowledge on plants is a compel-
ling source for the discovery of potent antimalarial mole-
cules; in fact major anti-malarial drugs such as quinine,
artemisinin and their derivatives are products of scien-
tific exploitation of traditional knowledge on the medi-
cinal properties of Cinchona spp and Artemisia annua
respectively.
Anti-malarial remedies are still widely employed and
culturally accepted by communities; people use herbs for
therapy, prevention [20,21] and for mosquito repellence
[22-24]. In several countries standardized herbal prepa-
rations are available and are considered for the use as
first line therapeutic intervention in the absence of ACTs
[25]. Relying on the effects of multiple bio-active com-
pounds, herbal anti-malarial medicines are less prone toinduce development of parasite resistance and if applied
at a large scale, have the potential to reduce drug pres-
sure for the development of resistance to ACTs [25].
In Mali an anti-malarial phytomedicine based on
Argemone mexicana has recently been included into
the national pharmacopeia as a validated herbal treat-
ment for the management of malaria following a
successful randomised controlled trial of the herbal
remedy vs artesunate amodiaquine [26]. A “clinical re-
covery” rate of 89% (without need for a second line
treatment) was recorded for A. mexicana treated pa-
tients compared to 95% for individuals of the artesu-
nate amodiaquine control group [26].
Several plant species have been shown to exhibit anti-
malarial properties (reviewed in [27]) but only a few have
been found to possess a secondary metabolite profile that
supports practical utilization for the development of stan-
dardised remedies and improved phytomedicines. As an
example, for centuries the neem tree (Azadirachta indica)
has given rise to various medicinal preparations for the
treatment of malaria and other illnesses in many parts of
the world [28,29]. The success of neem is derived from its
broad spectrum properties against parasites and other
infective agents (reviewed in [30]), due in part to its rich
sources of limonoids which are highly oxygenated terpe-
noids with insecticidal, anti-microbial, anti-inflammatory
and immuno-modulatory activities among other biological
properties [30,31].
Azadirachtins, in particular, exhibit potent insect hor-
mone regulatory properties, interfering with various
physiological processes of both larval and adult stages of
disease vector species [30]. Studies conducted on the
Chagas disease vector Rhodnius prolixus have shown
that azadirachtin A, taken up orally through blood feed-
ing by the insect, caused a reduction in oocyst growth
and egg production in a dose dependent manner [32].
Azadirachtin A administered orally in sucrose to Culex
tarsalis and C. quinquefasciatus females suppressed
blood feeding, reduced the oviposition rate, the size of
the egg raft, the hatching rate and longevity of the
treated insects [33]. Studies conducted with commercial
azadirachtin A enriched neem formulations (NeemAzal®
T/S 1.2 percent EC, Trifolio-M GmbH), evidenced larvi-
cidal and emergence inhibitory effects on An. stephensi, C.
quinquefasciatus and Aedes aegypti larval stages [34].
We previously observed impairment in blood intake,
oogenesis and oviposition in An. stephensi by a NeemA-
zal® formulation with an azadirachtin A content of 34%.
The effects observed revealed to be dose dependent and
were observed both in females having received NeemAzal®
in blood through membrane feeding and females that had
ingested the product with sucrose solution and were pro-
vided subsequently with an untreated blood meal [35]. In
a successive study, NeemAzal® was found to completely
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when administrated through a blood meal on gametocyte-
mic mice treated with NeemAzal® at a azadirachtin A con-
centration of 50 mg/kg [36]. Recently, the transmission
blocking effect by NeemAzal® was confirmed in P. falcip-
arum. A complete blockade of mosquito infection was
demonstrated in Anopheles coluzzii females membrane fed
on gametocytemic blood from P. falciparum infected pa-
tients containing NeemAzal® at a dosage of 70 μg/ml, while
an 80% prevalence reduction was observed at 50 μg/ml
[37]. Examination of midgut smears from An. stephensi
mosquitoes 20 hrs after having fed on NeemAzal® treated
P. berghei infected mice indicated that early sporogonic
stages were the main targets of the product [36].
Neem extracts also show in vitro activity on asexual
and sexual blood stages of P. falciparum , with gedunin,
nimbolide, and nimbinin being the most active constituents
[38]. The inhibition of chloroquine- and pyrimethamine-
resistant strains also, suggests that neem possesses a differ-
ent mode of action than that of the two drugs [38]. More
recently, a neem fruit extract (EtOAc phase) was
found to possess prominent in vitro antimalarial activ-
ity (IC50 ~ 2 μg/ml) that could be attributed to the
abundant presence of azadirone, gedunin and neem-
fruitin A, all of which have the ability to inhibit P.
falciparum D10 and W2 laboratory strains [39].
Furthermore, the different metabolites present in the
extracts could have multiple mechanisms of action, a
property that can slow down or negate the develop-
ment of parasite resistance. Hence, based on its mul-
tiple stage anti-plasmodial as well as insect regulatory
properties, neem represents a very good candidate for
the development of a phytomedicine exhibiting at a
time preventive, transmission blocking and mosquito-
cidal activities.
On the basis of the illustrated knowledge, we devel-
oped a novel concept to mirror a real life situation where
people regularly take a neem-based phytomedicine and
therefore expose Anopheles mosquitoes to repeated neem-
containing blood meals. Female anophelines are anthropo-
philic and feed every 2 to 4 days per oviposition cycle,
therefore mosquitoes could be exposed to multiple neem-
containing blood meals during their lifespan. We there-
fore, hypothesized that neem-treated blood meals will
have cumulative biological effects on Anopheles mosqui-
toes in such a setting which may affect them as a popula-
tion and impact on their vectorial capacity. This study was
designed to characterize the effects of repeated NeemAzal®
treatments on An. stephensi feeding capacity, fecundity
(oviposition rates) and fertility (egg hatchability). Such an
impact, together with neem antiplasmodial activity in the
vector, may lead to blockage of parasite transmission. If
this hypothesis is supported, the design and development
of a preventive, transmission blocking and “anti-vectorial”neem formulation, guided by translating the accumulated
knowledge on the biological effects of azadirachtin and
other neem limonoids, could appear feasible.
Methods
Experimental animals
Five to seven days old An. stephensi females were used.
Mosquito colonies were maintained at 30°C, > 75% rela-
tive humidity and 12:12 hrs light to dark photoperiod
cycle as described elsewhere [40]. Eggs laid on moist fil-
ter paper were transferred to water basins for hatching.
Hatched larvae were reared in well water and fed with
grounded laboratory mouse food (Mucedola S.R.L, Mi-
lano, Italy). Pupae were transferred to small water con-
tainers and placed in screened cages (18 × 18 × 18 cm)
for adult emergence. Adult mosquitoes were given 5%
sucrose ad libitum through soaked cotton pads.
Female BALB/c mice (20 - 25 g) were used as a source
of treated blood meals for experimental mosquitoes.
Mice were reared in the animal facilities of the Univer-
sity of Camerino, Italy. Rearing and handling of experi-
mental animals were in full compliance with the Italian
Legislative Decree on the “protection of animals used for
experimental and other scientific purposes” (D. Lgs. 116
of 01/27/92), and in full adherence with the European
Directive 2010/63/UE.
NeemAzal®
NeemAzal® technical grade batch number 052 (Trifolio-
M, GmbH, Lahnau, Germany) was used for the experi-
ments. NeemAzal® is a methanolic standardized extract
from Azadirachta indica seed kernels containing about
55% limonoids. According to the manufacturer, these in-
clude 33% azadirachtin A, 16% other azadirachtins (B to K),
4% salannin and 2% nimbin. NeemAzal® also contains 5%
fatty acids and other seed kernel components.
A sample of NeemAzal® (1.015 g) taken from the batch
number 052 (Trifolio-M, GmbH, Lahnau, Germany) was
subjected to column chromatography purification over
silica gel (230–400 mesh) using a gradient of eluents of
increasing polarity from n-hexane/ethyl acetate (EtOAc)
8:2 to EtOAc and then to EtOAc/methanol 1:1. Fourteen
fractions (1–14) were thus collected and their composition
was analyzed by NMR (on Varian INOVA 500 MHz
instrument) and MS (on a LTQ OrbitrapXL Thermo
Scientific mass spectrometer) and compared with data
published in the literature. This analysis allowed the
identification of pure azadirachtin A in fractions 7–8
(eluted with n-hexane/EtOAc 4:6), while fraction 6
contained azadirachtin A in mixture with less polar
azadirachtins and fraction 9 contained azadirachtin A
in mixture with more polar azadirachtins. The amount
of azadirachtin A proved to be approximately 520 mg
(about 51% of the sample), while the remaining
Percent hatchability ¼ Number of larvae hatched
Total number of eggs introduced
 100
ð1Þ
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(about 5% of the sample).
Preparation and administration of NeemAzal®
A NeemAzal® stock solution was prepared in absolute
ethanol, at an azadirachtin A concentration of 50 mg/
ml. The stock solution was then diluted to obtain final
dosages of 60, 105 and 150 mg of azadirachtin A per kg
of mouse body weight. PBS (pH 6.5) with 7.5% Tween
80 and 10% DMSO was used as solvent. Mice were
treated intraperitoneally with 100 – 200 μl per animal.
Control mice received equal volumes of the solvent solu-
tion [36]. For mosquito feeding, mice were narcotized
with 100 μl of a 13.1% mixture of xylazine and acepro-
mazine (1:1 ratio) in PBS (pH 7.2).
Experimental blood meals
Experimental mosquitoes received a total of 5 NeemA-
zal®-treated blood meals at azadirachtin A doses of 60,
105 and 150 mg/kg, once every 4 days. The study was
organized in 3 consecutive experiments, one for each
NeemAzal® dose. Four treatment and 4 control group
cages containing 150–200 females were used at each
NeemAzal® dose, and at each experimental blood meal
one treated mouse was exposed to each mosquito cage.
Relatively high mosquito survival and feeding rates
(80-95%) in both treatment and control groups, allowed to
remain with 59 – 81 mosquitoes per cage (4 cages per
group) after the fourth blood meal for evaluation of the
last experimental feeding event.
Experimental mice were narcotised thirty minutes
after the administration of the test solutions, placed on
the top of the mosquito cages and exposed to mosquito
females for about 1 hour. On the following day, engorged
females were counted after cold-immobilization. Males
and unfed females were discarded. Gravid females were
allowed to lay eggs before the following blood meal.
Estimation of blood meal size (feeding capacity)
The impact of NeemAzal® on the feeding capacity was
estimated by measuring the haematin content of the rec-
tal fluid excreted by the mosquitoes during the blood
meal. Briefly, the rectal fluid was collected in Petri dishes
(15 cm diameter) positioned in the cages below the feed-
ing mosquitoes. The content of each Petri dish was
dissolved in 20 ml of 0.1 M NaOH and incubated over-
night, to allow complete conversion of haemoglobin to
haematin. To remove blood cell debris, the mixture was
spun at 13,000 rpm for 10 minutes [41]. The supernatant
containing haematin was serially diluted (6 two-fold di-
lutions) and aliquots of 200 μl transferred to a 96-well,
flat-bottomed microplate (Nunc, Denmark). The absorb-
ance of samples was measured at 392 nm using a
FLUOstar Omega spectrophotometer (BMG labtech,Germany). Haemin (Sigma-Aldrich, Italy), was dissolved
in 0.1 M NaOH and the haematin solution obtained was
used to prepare a calibration curve [42]. The amount of
haematin in rectal fluid samples was estimated by extrapo-
lation of the sample’s optical density onto the standard
curve. The mean percent reduction in blood meal size was
calculated using Abbott’s formula [43] as in the equation
below.
Percent reduction in feeding capacity
¼
 
1−
Mean haematin content in NeemAzal group ðμg=mosquitoÞ
Mean haematin content in control group ðμg=mosquitoÞ
!
100
Means were derived from four replicates (mosquito
cages) per group.
Estimation of oviposition capacity
Two days after each blood meal administration, gravid
females were provided with wet filter paper discs for ovi-
position for 2 subsequent nights [35]. The number of
eggs laid on the paper discs were then quantified by im-
aging analysis, as previously described [44]. The mean
percent reduction in oviposition was evaluated using the
equation below:
Percent reduction in oviposition
¼

1−
Mean number of eggs laid in NeemAzal ‐treated group
Mean number of eggs laid in control group

100
Means were derived from four replicates (mosquito
cages) per group.
Assessment of hatchability
To evaluate the impact of NeemAzal® on egg hatchability,
200 eggs per treatment group (50 per replicate) were
seeded in 250 ml plastic beakers containing fresh well
water. Care was taken to thoroughly mix the eggs on the
soaked ovipositor paper discs before sampling. Egg hatch-
ing was monitored for a period of 72 hours. This was
based on our preliminary findings which showed that, in
both control and NeemAzal® treated groups, hatching was
completed within 48 hours; beyond this incubation period,
no more eggs hatched into larvae. The percent hatchabil-
ity and the percent reduction in hatchability were evalu-
ated using equations (1) and (2) below, respectively.
®
®
Percent reduction in hatchability
¼

1−
Number of larvae hatched in NeemAzal ‐treated group
Number of larvae hatched in control group

100
ð2Þ
®
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Data were entered in Excel (Microsoft Co.) and analysed
using Excel, Statistical Package for Social Scientists
(SPSS) and GraphPad Prism 5 (GraphPad Prism Inc).
Comparisons between means of treatment and control
groups were performed using Student’s t-test. Chi-square
test was used to compare group proportions.Results
Effect of repeated NeemAzal® exposure on An. stephensi
feeding capacity
During the first 3 blood meals, the average proportion
of fed mosquitoes was not different in treated and
control groups ranging from 80% to 95% (Table 1).
However, a reduction in feeding of about 8% was
noted at the fourth and fifth blood meal in the 105
and 150 mg/kg NeemAzal®-treated groups. The pro-
portions of fed An. stephensi, in the 105 mg/kg treat-
ment group compared to controls, were reduced by
9% (p = 0.0218) and 8% (p = 0.0373) at the fourth and
fifth blood meal respectively. At the highest treatment
dose, the proportion of engorged females was found toTable 1 Mean numbers and proportions of An. stephensi mos
each of the 5 consecutive blood meals
Neem-Azal®
dose
Blood
meal
fed mosquitoes in NeemAzal®- treatm
mean n.1) ± SD2) %
150 mg/kg 1 118 ± 7 8
2 84 ± 11 8
3 81 ± 11 9
4 71 ± 9 8
5 57 ± 8 8
105 mg/kg 1 118 ± 11 8
2 83 ± 4 9
3 77 ± 7 9
4 59 ± 11 8
5 56 ± 9 8
60 mg/kg 1 139 ± 10 8
2 108 ± 10 9
3 86 ± 14 9
4 73 ± 12 9
5 59 ± 7 9
1)mean n. = arithmetic mean number of 4 mosquito replicate cages per treatmentbe reduced by 7% (p = 0.05) and 8% (p = 0.0251) respect-
ively, at the fourth and fifth NeemAzal® exposure (Table 1).
Taking into account the number of fed mosquitoes,
exposure to repeated NeemAzal®-treated blood meals re-
duced the mosquito feeding capacity compared to their
control counterparts in a dose dependent manner. At a
dose of 60 mg/kg azadirachtin A, a reduction of feeding
capacity of about 50% was observed after the fourth
blood meal (Figures 1a and 2). At 105 mg/kg of azadir-
achtin A, a significant reduction of 40% in feeding cap-
acity was already obtained after the second blood meal
(Figures 1b and 2) and at the highest dose tested
(150 mg/kg) the mosquito feeding capacity was reduced
by 50% or more from the second blood meal onwards
(Figures 1c and 2). At this dose the percent feeding re-
duction was over 20% higher than that observed in the
60 mg/kg treatment groups.
The extent of feeding capacity of control mosquitoes,
as estimated through the haematin quantification in rec-
tal fluid, showed an increasing trend in subsequent
blood meals. In particular, a marked increase was ob-
served in the control groups of the 105 and 150 mg/kg
dosage experiments from the first to the second blood
meal (Figure 1). Such a feeding pattern is characteristic
of different mosquito species as previously reported [45].
Effect of NeemAzal® on oviposition
The administration of NeemAzal® through repeated
blood meals also affected oviposition of An. stephensiquitoes fed on NeemAzal®-treated and control mice at
ent groups Fed mosquitoes in control groups
(CI95)
3) mean n. ±SD % (CI95)
6 (79–93) 117 ± 14 87 (83–90)
9 (85–93) 92 ± 15 93 (92–94)
1 (86–97) 82 ± 14 93 (91–95)
5 (81–90) 81 ± 17 92 (88–96)
5 (81–90) 71 ± 18 93 (90–96)
2 (76–89) 118 ± 20 82 (75–89)
2 (90–94) 82 ± 3 93 (92–94)
0 (83–97) 72 ± 6 90 (87–94)
1 (70–91) 70 ± 5 90 (86–93)
2 (75–89) 64 ± 3 90 (86–94)
0 (71–89) 117 ± 18 81 (69–93)
5 (94–97) 81 ± 10 90 (85–94)
1 (90–92) 72 ± 14 90 (88–92)
4 (91–96) 63 ± 12 94 (92–97)
2 (88–96) 54 ± 8 95 (92–97)
group; 2) ± SD = standard deviation; 3) CI95 = confidence interval at 95%.
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dependent manner (Figure 3).
Mosquitoes fed on NeemAzal®-treated blood meals
laid significantly less eggs over subsequent blood meals
compared to their control counterparts at all tested dos-
ages (Figure 3 and 4). The inhibition in oviposition was
most pronounced when mosquitoes fed on mice treated
with 150 mg/kg dose of NeemAzal®; at this dosage, after
the second blood meal, egg laying was already reduced
by about 50% (p = 0.0064) in the treated group compared
to their control counterparts. Similar reductions inFigure 1 Blood meal sizes per fed Anopheles stephensi female followi
105 mg/kg and (c) 150 mg/kg (light bars) or solvent as control (dark bars).
NA represents NeemAzal®; vertical lines represent 95% confidence intervaloviposition of about 60% (p = 0.003) and 50% (p = 0.007)
were observed in the 105 mg/kg and 60 mg/kg treat-
ment groups respectively, after the fifth blood meal.
Calculating the number of eggs laid per female mosquito
revealed a very similar impact of repeated NeemAzal®
treatment on oviposition as observed for feeding. This
effect on oviposition appeared to be a consequence of re-
duced blood intake, given that when the numbers of eggs
were calculated per μg of haematin, no evidence of differ-
ences emerged between treatment and control females as
shown in Figure 5.ng treatment with different NeemAzal® doses. (a) 60 mg/kg, (b)
BM indicates subsequent blood meals on the same mosquito batches;
and ns indicate not significant.
Figure 2 Dose- and frequency-dependent effect of repeated NeemAzal® treatment on feeding capacity. BM indicates subsequent blood
meals on the same mosquito batches.
Dembo et al. Parasites & Vectors  (2015) 8:94 Page 7 of 13Effect of NeemAzal® on hatchability
The fertility of female mosquitoes fed on NeemAzal®-
treated BALB/c mice was affected significantly (p < 0.05)
at the doses tested, i.e. 105 and 150 mg/kg (Figure 6). At
105 mg/kg, a 16% reduction in egg hatchability (p =
0.0008) was observed after the second blood meal, which
gradually increased to 62% (p < 0.0001) after the fifth
blood meal. At the 150 mg/kg dose, a 63% hatchability
reduction (p < 0.0001) was already observed after the
third blood meal, which reached up to 70% (p < 0.0001)
after the fifth blood meal.
Discussion
Neem extracts containing azadirachtin and other bio-
active secondary metabolites are used by many com-
munities worldwide in controlling different disease
vectors as well as in treatment of malaria and other
parasitic diseases. Studies employing direct feeding on
neem metabolites or administration through artificial
blood meals have shown that insects ingesting azadir-
achtin and other neem limonoids display reduced
fitness due to feeding deterrence, delays in larvae
and nymph development, incomplete ecdysis, mal-
formed pupae and adults and reduced fecundity and
fertility [30].
In feeding experiments conducted on Culex tarsalis
and C. quinquefasciatus, blood-feeding activity was
found to be suppressed when newly emerged adults were
fed continuously on 10 parts per million (ppm) or
50 ppm azadirachtin in 10% sucrose solutions for 7 days
[33]. Earlier work conducted by our group demonstrated
anti-feedant effects of NeemAzal® on An. stephensi after
administration of the product by membrane feeding of
medicated blood or when offered to females in sucrosesolution [35]. When females were pre-treated with
NeemAzal®-medicated sucrose solution at 100 or 10
μg/ml azadirachtin A equivalents, their blood intake at
two subsequent blood meals was significantly reduced.
Mosquitoes given NeemAzal® at the same dosages by
blood membrane feeding showed reduced feeding at the
second but not at the first blood meal. Similarly, in our
study reported here, an impact on feeding emerged only
from the second blood meal onwards in mosquitoes fed
on mice intraperitoneally treated with NeemAzal® at an
azadirachtin A dosage of 105 and 150 mg/kg. The fact
that comparable secondary anti-feedant effects were
found after neem feeding on a treated mammalian host,
suggests that azadirachtin, conserves its bioactive mo-
lecular conformation and its bioavailability in the mouse,
at least briefly.
Calculating the number of eggs laid per female re-
vealed a very similar impact of repeated NeemAzal®
treatment on oviposition to that observed for feeding.
Egg numbers were significantly reduced in the 150 and
105 mg/kg treatment groups from the first and second
blood meal onwards, respectively, and an oviposition re-
duction of more than 50% was observed after the fifth
blood meal at all the tested dosages. The effect on ovi-
position appeared to be mainly a consequence of re-
duced blood intake, since no difference was observed
between treatment and control females with regards to
the numbers of eggs per μg of haematin excreted in the
rectal fluid of blood sucking mosquitoes, which was used
as a feeding estimate. In our previous study, whereby
NeemAzal® was administered through membrane feed-
ing, a significant reduction in the numbers of eggs per μl
of blood was recorded in the 100 μg/ml group after the
second blood meal, but no oogenesis inhibitory effect on
Figure 3 Effects of different doses of NeemAzal® on oviposition. (a) 60 mg/kg, (b) 105 mg/kg, (c) 150 mg/kg (light bars) and solvent control
(dark bars). BM indicates subsequent blood meals on the same mosquito batches; NA represents NeemAzal®; vertical lines represent 95%
confidence interval; ns indicate not significant.
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NeemAzal® medicated sucrose solution [35].
For comparison, in C. tarsalis and C. quinquefasciatus
the oviposition rate and size of egg raft was found to be
reduced when females were fed on sucrose solutions
containing 10 ppm azadirachtin before blood feeding
[33]. Studying the azadirachtin effects on the haema-
tophagous vector of chagas desease Rhodnius prolixus,Garcia and colleagues (1990) observed a strong reduc-
tion of the number of eggs laid by females after adminis-
tration of 1 and 5 μg/ml azadirachtin by membrane
feeding [46]. By administering 3 consecutive plain blood
meals after the treated one, the effect was found to be ir-
reversible in the 5 μg/ml group and only partially revers-
ible at 1 μg/ml. The authors hypothesized that small
amounts of azadirachtin may stably bind to various
Figure 4 Dose- and frequency-dependent effect of NeemAzal® treatment on suppression of oviposition. BM indicates subsequent blood
meals on the same mosquito batches
Dembo et al. Parasites & Vectors  (2015) 8:94 Page 9 of 13insect organs including brain, prothoracic glands and
ovaries and thus interfere with endocrine regulation
[46,47]. An irreversible impact on vitellogenesis was also
observed by Dhar and colleagues [48], studying the ef-
fects of long-term exposure to neem volatiles on An. ste-
phensi and An culicifacies females. From this study it
emerged that neem components can exert biological ef-
fects also after absorption through the cuticle or passage
through spiracles (Dhar 1996).
Morphological alterations of the ovaries were re-
ported and discussed in our earlier publications on
azadirachtin A effects in An. stephensi [35]. The ultra-
structural investigations on ovaries from NeemAzal®-
treated females revealed distinct structural modifica-
tions indicative of a complete block of oogenesis,
impairment of vitellogenesis, vitelline envelope forma-
tion, and degeneration of follicle cells. Morphologically
altered ovarioles were recorded next to structurally
normal ones. The results of the ultrastructural study
suggested that NeemAzal® impairs hormone control of
oogenesis and exerts a cytotoxic effect on both follicu-
lar cells and oocytes [35]. These findings are in line
with earlier observations in other insects suggestive of
detrimental effects of azadirachtin A on the neurohor-
mone producing gland [49], reproductive tissue [50] as
well as on gut epithelial cells [51]. On the basis of the
discussed mode of azadirachtin A action, the impact
of NeemAzal® on egg hatchability recorded in this
study was not an unexpected finding. The proportion
of eggs that were able to hatch was reduced in the 105
and 150 mg/kg treatment group from the second
blood meal onwards. At these dosages hatchability wasinhibited by more than 60% and 70%, respectively, after
the fifth blood meal taken by the females on NeemA-
zal®-treated mice.
In our study, the survival of mosquitoes appeared not
to be affected by the repeated NeemAzal® administration
even at the highest tested dosage (data not shown). This
finding is in line with other azadirachtin studies that
showed a moderate impact on insect longevity in re-
peated exposure schemes [33,46]. Azadirachtin exerts
cytotoxic effects at high concentrations; however, in
Rodnius prolixus and Locusta migratoria the com-
pound was found to be rapidly metabolized and ex-
creted in the form of dihydroazadirachtin although
small amounts could be retrieved in the head and vis-
ceral tissues weeks after its application [52,53].
Taken together, these findings are very encouraging
and warrant further studies in human hosts consum-
ing neem-based preparations for various purposes.
These natural products are eco-friendly and not toxic
to humans and other vertebrate hosts according to
studies conducted by Al Sharook [54]. If scientifically
validated and produced as standardized phytomedi-
cines may play a prominent role in malaria control
programmes of endemic regions. In Nigeria for in-
stance, a standardised neem leaf extract traded as
IRACARP® is being used in the management of pa-
tients co-infected with malaria and HIV [55]. In
Kenya, prophylactic neem extracts are being marketed
as Neem herbal tea, a nutraceutical product that pro-
vides a minimum of 22 mg/kg neem leave extracts per
tea bag [56]. The use of standardised phytomedicines
in situations where access to antimalarial drugs is
Figure 5 Estimated amount of eggs produced per μg haematin at different NeemAzal® doses, (a) 60 mg/kg, (b) 105 mg/kg and (c)
150 mg/kg. BM indicates subsequent blood meals on the same mosquito batches; NA represents NeemAzal®; vertical lines represent 95%
confidence interval.
Dembo et al. Parasites & Vectors  (2015) 8:94 Page 10 of 13hampered or delayed might save lives, particularly in
children who are at high risk of rapidly developing se-
vere forms of the disease [25].
All the above observations indicate the need for field
trials to assess the curative efficacy and safety of neem-
based products already in use. In areas where members
of communities regularly use neem during high trans-
mission seasons to prevent malaria episodes, it would be
highly interesting to assess and dissect the prophylactic
and transmission blocking efficacy of such traditional
remedies at a community level.Conclusions
The diffused use of neem in the treatment of malaria
and its well known insect growth regulatory properties
guided this study of the multi-factorial effects of this
plant extract on the mosquito vector fitness in vivo using
the mouse as the vertebrate host and An. stephensi as
the vector. Our results show that repeated exposure to
NeemAzal®-treated blood meals can result in a cascade
of events leading to a significant reduction in the fitness
of An. stephensi. The mosquito feeding capacity, ovipos-
ition and egg hatchability are all decreased in a dose and
Figure 6 Proportion of Anopheles stephensi eggs that hatched into larvae at different NeemAzal® doses, (a) 105 mg/kg, (b) 150 mg/kg
(light bars) and in control groups (dark bars). BM indicates subsequent blood meals on the same mosquito batches; NA represents
NeemAzal®; vertical lines represent 95% confidence interval.
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thetical field situation of a community regularly con-
suming neem treatments and thus exposing the
Anopheles vectors repeatedly to the bioactive compo-
nents, cumulative effects as demonstrated here for the
product NeemAzal® may potentially block the trans-
mission of malaria parasites by disrupting the vector
fitness and, consequently, vectorial capacity.
The findings from this study and previous work
highlight the challenging prospect of designing formu-
lations on the basis of neem plant parts rich in azadir-
achtin A as multi-target herbal medicines exhibiting
curative, preventive, transmission-blocking and anti-
vectorial properties.Competing interests
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